ACP
RARE icon

Acuta Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Acuta Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-46,000
Closed -$2.13M – 80
2017
Q4 		$2.13M Buy
+46,000
New +$2.26M 0.4% 36

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acuta Capital Partners's RARE Position: Q3 2025 in Review

Acuta Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 23,814 shares — an estimated $866K sold.

Acuta Capital Partners first reported a position in RARE in Q1 2024 and held it in 5 quarters. The position peaked at $1.39M in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Acuta Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 23,814 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $866K.
  • Acuta Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 5 quarters.
  • Acuta Capital Partners's Ultragenyx Pharmaceutical position peaked at $1.39M in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.